Medical Journal. A draft prepared by the FDA in which certain requirements are proposed that biosimilar drug labels will have to meet from now on will be submitted for evaluation.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
